Carlyle and SK Capital to take gene therapy firm bluebird bio private
The Carlyle Group and SK Capital Partners have agreed to acquire bluebird bio, Inc, a Somerville, Massachusetts-based gene therapy firm, in a take-private deal. According to terms of the agreement, bluebird stockholders will receive $3 per share in cash.
The Carlyle Group (NASDAQ:CG – Get Free Report) was downgraded by equities research analysts at StockNews.com from a “hold” ...
Carlyle Group's distributable fourth-quarter earnings missed market expectations on Tuesday, eclipsing a strong growth in the ...
Private equity firms Carlyle Group Inc. and Thoma Bravo are among the suitors shortlisted in the bidding for French software ...
(Reuters) - U.S.-based investment firm Carlyle Group has entered India's auto components market by buying a controlling stake ...
Carlyle Group Inc.’s stock fell 5% on Tuesday after the private-equity firm signaled a slowdown in its fee-related earnings ...
The Carlyle Group Inc (CG) reports a near 30% increase in fee-related earnings and outlines future growth strategies amid ...
Bank of America Securities analyst Craig Siegenthaler maintained a Sell rating on Carlyle Group (CG – Research Report) yesterday and set a ...
AlpInvest Secondaries Fund VIII has raised nearly $9.4 billion as of 31 December 2024, according to materials prepared for ...
The Carlyle Group has announced the listing of its portfolio company Hexaware Technologies, a global IT services company, on the Bombay Stock Exchange and National Stock Exchange in India. The total ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback